The same group also investigated the effects of the CD38-targeted monoclonal antibody daratumumab against a range of AML cell lines and found that daratumumab-induced apoptosis was not correlated with CD38 expression levels. This evidence concerns the gene CD38 and acute myeloid leukemia.